Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Temple

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Advances in Genetics|October 21, 2020
The efficient Lamarckian spread of life in the cosmosEdward J Steele, Reginald M Gorczynski, Robyn A Lindley, et al.
Epilepsia|July 24, 2015
Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standardTricia Y Ting, Wenlei Jiang, Robert Lionberger, et al.
JAMA Network Open|October 14, 2022
Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019S W Johnny Lau, Yue Huang, Julie Hsieh, et al.
American Heart Journal|April 29, 2008
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005Kevin Jackson, Bernard J Gersh, Norman Stockbridge, et al.
The Journal of Clinical Psychiatry|April 11, 2014
Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug AdministrationSilvana Borges, Yeh-Fong Chen, Thomas P Laughren, et al.
American Heart Journal|February 26, 2008
Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issuesE Marc Jolicoeur, E Magnus Ohman, Robert Temple, et al.
American Heart Journal|May 15, 2018
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?Noel Chan, Philip T Sager, Jack Lawrence, et al.
Clinical Trials (London, England)|February 16, 2012
Panel discussion 2Susan Ellenberg, Bryan Luce, Tom Fleming, et al.
Nature Reviews. Drug Discovery|July 20, 2007
The FDA's assessment of follow-on protein products: a historical perspectiveJanet Woodcock, Joseph Griffin, Rachel Behrman, et al.
Expert Review of Neurotherapeutics|December 27, 2014
Charting a path toward combination therapy for Alzheimer's diseaseDiane Stephenson, Dan Perry, Cynthia Bens, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Advances in Genetics|October 21, 2020
The efficient Lamarckian spread of life in the cosmosEdward J Steele, Reginald M Gorczynski, Robyn A Lindley, et al.
Epilepsia|July 24, 2015
Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standardTricia Y Ting, Wenlei Jiang, Robert Lionberger, et al.
JAMA Network Open|October 14, 2022
Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019S W Johnny Lau, Yue Huang, Julie Hsieh, et al.
American Heart Journal|April 29, 2008
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005Kevin Jackson, Bernard J Gersh, Norman Stockbridge, et al.
The Journal of Clinical Psychiatry|April 11, 2014
Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug AdministrationSilvana Borges, Yeh-Fong Chen, Thomas P Laughren, et al.
American Heart Journal|February 26, 2008
Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issuesE Marc Jolicoeur, E Magnus Ohman, Robert Temple, et al.
American Heart Journal|May 15, 2018
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?Noel Chan, Philip T Sager, Jack Lawrence, et al.
Clinical Trials (London, England)|February 16, 2012
Panel discussion 2Susan Ellenberg, Bryan Luce, Tom Fleming, et al.
Nature Reviews. Drug Discovery|July 20, 2007
The FDA's assessment of follow-on protein products: a historical perspectiveJanet Woodcock, Joseph Griffin, Rachel Behrman, et al.
Expert Review of Neurotherapeutics|December 27, 2014
Charting a path toward combination therapy for Alzheimer's diseaseDiane Stephenson, Dan Perry, Cynthia Bens, et al.
Pageof 9